Drug combination of topical ripasudil and brimonidine enhances neuroprotection in a mouse model of optic nerve injury

Namekata, Kazuhiko; Noro, Takahiko; Nishijima, Euido; Sotozono, Akiko; Guo, Xiaoli; Harada, Chikako; Shinozaki, Youichi; Mitamura, Yoshinori; Nakano, Tadashi; Harada, Takayuki

doi:10.1016/j.jphs.2024.02.011

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An in vivo study was conducted to treat adult mice with optic nerve injury using topical ripasudil, brimonidine, or a combination of both drugs. The study found that topical ripasudil suppressed expression of TNFα, IL-1β, and monocyte chemotactic protein-1, thus accounting for RGC rescue after optic nerve injury, and also proved that the combination of both drugs was more effective than a single treatment with either ripasudil or brimonidine [ 58 ]. However, it is important to note that these findings are limited to animal models, where the dosage of ripasudil or brimonidine differs from that used in clinical trials for patients with ocular hypertension.…”

Section: Recent Trials Of Rho Kinase Inhibitors In Glaucoma Treatmentmentioning

confidence: 99%

The Application of Rho Kinase Inhibitors in the Management of Glaucoma

Liu,

Chen,

2024

IJMS

View full text Add to dashboard Cite

Glaucoma is a chronic neurodegenerative disease that poses a significant threat of irreversible blindness worldwide. Current treatments for glaucoma focus on reducing intraocular pressure (IOP), which is the only modifiable risk factor. Traditional anti-glaucomatous agents, including carbonic anhydrase inhibitors, beta-blockers, alpha-2 agonists, and prostaglandin analogs, work by either improving uveoscleral outflow or reducing aqueous humor production. Rho kinase (ROCK) inhibitors represent a novel class of anti-glaucomatous drugs that have emerged from bench to bedside in the past decade, offering multifunctional characteristics. Unlike conventional medications, ROCK inhibitors directly target the trabecular meshwork outflow pathway. This review aims to discuss the mechanism of ROCK inhibitors in reducing IOP, providing neuroprotection, and preventing fibrosis. We also highlight recent studies and clinical trials evaluating the efficacy and safety of ROCK inhibitors, compare them with other clinical anti-glaucomatous medications, and outline future prospects for ROCK inhibitors in glaucoma treatment.

show abstract

Section: Recent Trials Of Rho Kinase Inhibitors In Glaucoma Treatmentmentioning

confidence: 99%

The Application of Rho Kinase Inhibitors in the Management of Glaucoma

Liu,

Chen,

2024

IJMS

View full text Add to dashboard Cite

show abstract

The Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy

Quillen,

Kimball,

Ritter-Gordy

et al. 2024

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies

Wang,

Huang,

Lin

2024

Pharmaceuticals

View full text Add to dashboard Cite

Glaucoma is a major global health concern and the leading cause of irreversible blindness worldwide, characterized by the progressive degeneration of retinal ganglion cells (RGCs) and their axons. This review focuses on the need for neuroprotective strategies in glaucoma management, addressing the limitations of current treatments that primarily target intraocular pressure (IOP) reduction. Despite effective IOP management, many patients continue to experience RGC degeneration, leading to irreversible blindness. This review provides an overview of both pharmacological interventions and emerging technologies aimed at directly protecting RGCs and the optic nerve, independent of IOP reduction. Pharmacological agents such as brimonidine, neurotrophic factors, memantine, Ginkgo biloba extract, citicoline, nicotinamide, insulin, and resveratrol show promise in preclinical and early clinical studies for their neuroprotective properties. Emerging technologies, including stem cell therapy, gene therapy, mitochondrial-targeted therapies, and nanotechnologies, offer innovative approaches for neuroprotection and regeneration of damaged RGCs. While these interventions hold significant potential, further research and clinical trials are necessary to confirm their efficacy and establish their role in clinical practice. This review highlights the multifaceted nature of neuroprotection in glaucoma, aiming to guide future research and clinical practice toward more effective management of glaucoma-induced neurodegeneration.

show abstract

Drug combination of topical ripasudil and brimonidine enhances neuroprotection in a mouse model of optic nerve injury

Cited by 3 publications

References 30 publications

The Application of Rho Kinase Inhibitors in the Management of Glaucoma

The Application of Rho Kinase Inhibitors in the Management of Glaucoma

The Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy

Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies

Contact Info

Product

Resources

About